H Scholz
Papers
1
Total Citations
25
H-Index
1
About
Hans-Joerg Scholz is a clinical researcher whose work centers on advancing treatment options for metastatic castration-resistant prostate cancer (mCRPC), a challenging stage of the disease. His major contribution lies in evaluating the real-world efficacy and safety of cabazitaxel, a chemotherapy agent used after disease progression on docetaxel. Scholz was a key author in a pivotal pooled analysis of the compassionate use and early access programmes for cabazitaxel, which synthesized data from over 1,500 patients across multiple centers. This study, cited 25 times, provided critical evidence that cabazitaxel maintains its therapeutic benefit in routine clinical practice, with manageable toxicity, thereby reinforcing its role as a standard-of-care option for mCRPC. By bridging the gap between clinical trials and everyday patient care, Scholz’s work has helped oncologists make informed treatment decisions for a population with limited alternatives. His research underscores the importance of real-world data in validating and optimizing cancer therapies, directly impacting clinical guidelines and patient outcomes in the field of genitourinary oncology.
Research Focus
Key Achievements
Top Papers
- 1